Eko, a San Francisco-based startup developing artificial intelligence for heart disease screening, telehealth and remote patient monitoring, closed a $65 million Series C funding round, according to a Nov. 9 Wall Street Journal report.
In January, the FDA approved two Eko algorithms used with its digital stethoscopes to detect heart murmurs and atrial fibrillation. Eko DUO stethoscopes equipped with the two algorithms and a single-lead ECG have been found in clinical studies to identify AFib with 99 percent sensitivity and 97 percent specificity, and heart murmurs with 87 percent sensitivity and 87 percent specificity.
Read more at Becker's Hospital Review
Please note: Murmur detection is part of Eko’s SENSORA™ Cardiac Disease Detection Platform. Contact our sales team to learn more.